Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


ASH: Geron's 'drug works' in myelofibrosis, despite 'possibly related' deaths

This article was originally published in Scrip

Executive Summary

Menlo Park, California-based Geron has revealed preliminary data from the ongoing Mayo Clinic investigator-sponsored trial (IST) for its telomerase inhibitor imetelstat, which is being tested as a treatment for myelofibrosis. Even though two patients out of 22 in the initial cohort have died, one of the investigators said that the drug "clearly shows antimyeloproliferative activity." Geron's CEO told investors that dose reductions during Mayo's trial meant that the myelosuppression side effect seen by some patients was "clearly manageable."


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts